Perceptive Advisors LLC Reata Pharmaceuticals Inc Transaction History

Perceptive Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$79.22 - $105.37 $119 Million - $158 Million	-1,499,070 Reduced 69.1%	670,206 $68.3 Million
Q1 2023 May 15, 2023	BUY	$30.85 - $93.17 $66.9 Million - $202 Million	2,169,276 New	2,169,276 $197 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $1.94 Million - $3.65 Million	100,000 New	100,000 $2.51 Million
Q2 2022 Aug 15, 2022	SELL	$20.71 - $36.5 $921,077 - $1.62 Million	-44,475 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$24.12 - $39.6 $1.07 Million - $1.76 Million	44,475 New	44,475 $1.46 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $76.44 $471,850 - $739,709	-9,677 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$35.64 - $92.06 $344,888 - $890,864	9,677 New	9,677 $791,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.